- Home
- NUKK vs IGC Comparison
NUKK vs IGC Comparison
Compare NUKK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- IGC
- Stock Information
- Founded
- NUKK 2013
- IGC 2005
- Country
- NUKK United States
- IGC United States
- Employees
- NUKK N/A
- IGC N/A
- Industry
- NUKK Blank Checks
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- IGC Health Care
- Exchange
- NUKK Nasdaq
- IGC Nasdaq
- Market Cap
- NUKK 37.7M
- IGC 39.8M
- IPO Year
- NUKK N/A
- IGC N/A
- Fundamental
- Price
- NUKK $8.00
- IGC $0.42
- Analyst Decision
- NUKK
- IGC Strong Buy
- Analyst Count
- NUKK 0
- IGC 2
- Target Price
- NUKK N/A
- IGC $4.00
- AVG Volume (30 Days)
- NUKK 3.6M
- IGC 695.2K
- Earning Date
- NUKK 11-14-2025
- IGC 11-11-2025
- Dividend Yield
- NUKK N/A
- IGC N/A
- EPS Growth
- NUKK N/A
- IGC N/A
- EPS
- NUKK N/A
- IGC N/A
- Revenue
- NUKK N/A
- IGC $1,327,000.00
- Revenue This Year
- NUKK N/A
- IGC $15.26
- Revenue Next Year
- NUKK N/A
- IGC $3.41
- P/E Ratio
- NUKK N/A
- IGC N/A
- Revenue Growth
- NUKK N/A
- IGC 24.95
- 52 Week Low
- NUKK $1.30
- IGC $0.25
- 52 Week High
- NUKK $78.32
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- NUKK 63.50
- IGC 52.73
- Support Level
- NUKK $7.60
- IGC $0.39
- Resistance Level
- NUKK $9.70
- IGC $0.43
- Average True Range (ATR)
- NUKK 0.91
- IGC 0.02
- MACD
- NUKK 0.26
- IGC -0.00
- Stochastic Oscillator
- NUKK 66.46
- IGC 44.42
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.